School Of Medicine Basic Sciences

University of California, San Diego biochemist Jin Zhang delivered a School of Medicine Basic Sciences Apex Lecture on April 17 about signaling networks and biosensor development. Read More

Congratulations to our School of Medicine Basic Sciences members who were promoted or received new appointments between January and March 2025. These individuals significantly enrich our pursuit of pathbreaking research and contribute to the growth and success of our school. Read More

Researchers discovered that the protein tenascin-C is a crucial molecular player in the aggressiveness of anaplastic thyroid cancer. The results could lead to better targeted therapeutics for thyroid cancer. Read More

Researchers from the Vanderbilt University Medical Center and Vanderbilt University have figured out how two bacterial elements present in only some Helicobacter pylori strains lead to molecular changes in host tissues that favor the development of gastric cancer. Read More

University of California, San Diego, Professor of Pharmacology Jin Zhang will present the Vanderbilt School of Medicine Basic Sciences Apex Lecture on April 17, 2025. Read More

University of California, San Diego, faculty member Ryan Hibbs delivered a School of Medicine Basic Sciences Apex Lecture on March 27, presenting about muscle acetylcholine receptors in development and disease. Read More

Meet Ashley Haddard, the senior program manager for research for the Department of Pharmacology in the Vanderbilt School of Medicine Basic Sciences. Read More

Anne Taylor, PhD'23, sat down with us to discuss her experience studying basic science at Vanderbilt and how it played a role in her career. Taylor is now a fellow at the Center for Opioid Research, Education & Outreach at the Auburn University Harrison College of Pharmacy. Read More

Meet David Baughman, the research program manager for the Vanderbilt Institute of Chemical Biology. Read More

Triple-negative breast cancer accounts for 10 percent of breast cancer cases in the U.S. annually. As T-cells that normally kill cancer cells often become exhausted and stop, Vanderbilt pharmacologists are seeking chemotherapy or targeted therapy approaches that can enhance the T-cell killing of cancer cells. Read More